ASM and BenchSci Partner to Bring ASM Journal Content to Scientists Using EMET

TORONTO and WASHINGTON – September 28, 2026 – ASM and BenchSci today announced a partnership that brings all 17 ASM journals to scientists working in EMET, BenchSci’s agentic research environment for preclinical drug discovery.

ASM’s journals represent one of the world’s most extensive collections of peer-reviewed microbiology research, spanning bacteriology, virology, antimicrobial resistance, and clinical diagnostics. However, the details scientists need most, such as the strain used, the drug concentration tested, or whether a result held up in a relevant model are usually buried in a paper’s methods and figures and can be difficult to identify through searches focused primarily on titles and abstracts.

This partnership addresses that gap. Since the agreement covers the full text of each paper, EMET can draw on the entire study, including methods, results, and discussion rather than the abstract alone. When a scientist asks a question, EMET shows the evidence behind its answer: the figures, figure legends, abstracts, and short excerpts it drew on, each linked to the original article on ASM’s site.

The agreement spans more than three decades of research, from 1990 to the present, and includes every new paper as ASM publishes it. The journals include Antimicrobial Agents and Chemotherapy, Journal of Virology, Infection and Immunity, Journal of Clinical Microbiology, mBio, and Clinical Microbiology Reviews. Scientists at organizations using EMET can access the full collection without needing a separate ASM subscription. Altogether, the collection adds roughly 750,000 figures from 224,000 articles.

The gain is largest in infectious disease, where ASM’s journals expand EMET’s coverage to 478,000 articles, a 39% increase. This includes research on the pathogens behind some of the most urgent threats to public health, among them E. coli, Salmonella, MRSA, drug-resistant Klebsiella, along with the resistance mechanisms and laboratory testing that anti-infective programs depend on. That depth gives scientists more of the published evidence to reason from, helping anti-infective programs move from question to experiment faster and accelerating the discovery of new medicines.

“ASM journals have long served as a trusted source of rigorous, peer-reviewed microbial science. By making this content more discoverable within EMET, this partnership will help scientists engage with the full context of the research, from methods and results to figures, while preserving clear attribution to the researchers who produced it. It is an important opportunity to extend the reach and impact of microbial science and help inform the next generation of discovery,” said Melissa Junior, Chief Publishing Officer, ASM.

“In microbiology, the experimental detail that matters lives in the figures and the methods, not the abstract. This partnership puts that detail in front of scientists at the moment they are deciding what to run next,” said Liran Belenzon, CEO and co-founder, BenchSci.

At the foundation of EMET is the Biological Evidence Knowledge Graph, which connects more than 850 million nodes through 2.2 billion relationship edges drawn from publications, patents, omics datasets, clinical trials, reagents, and experimental methods — harmonized against 38 million ontological entities and maintained by 60 PhD-level scientists. The agentic research environment puts that foundation to work, with agents that query, reason, and hand off across steps instead of returning one-off answers. Together they support systematic preclinical workflows from discovery through IND submission.

About the American Society for Microbiology

ASM is a global community shaping the future of the microbial sciences to tackle some of the world’s most pressing challenges. Established in 1899, ASM connects scientists across disciplines, sectors and borders to advance discovery, foster collaboration and drive innovation.

With more than 38,000 members and a global network that reaches millions, ASM accelerates scientific progress through publishing, convening, advocacy and professional development. From climate change and antimicrobial resistance to industrial, basic and applied microbiology, ASM empowers the microbial sciences community to create solutions that benefit society and build what’s next.

About BenchSci

BenchSci is a world leader in AI software for biopharma research and development on a mission to exponentially increase the speed and quality of life-saving R&D to help bring new medicines to patients faster. We apply AI to understand how disease biology works throughout the drug discovery pipeline to solve the number one reason drug discovery projects fail—getting the biology wrong. EMET, BenchSci’s agentic AI workbench, unifies data, models, workflows, and scientific reasoning into a single environment purpose-built for preclinical R&D — giving every scientist an agentic team of PhD scientists to reason through disease biology behind every question. Backed by top-tier investors, including Generation Investment Management, iNovia Capital, TCV, F-Prime, Gradient Ventures (Google’s AI fund), and Golden Ventures, BenchSci has raised over $200 million. Our platform accelerates science at 16 top-20 pharmaceutical companies and over 4,500 leading research centers worldwide. For more information about BenchSci, visit www.benchsci.com.